Gut microbiota and immunotherapy of renal cell carcinoma

Area of Science:

• Oncology
• Microbiology
• Immunology

Background:

• The gut microbiome is increasingly recognized for its role in cancer development and progression.
• Microbiome composition significantly impacts patient responses to immune checkpoint inhibitors (ICIs).

Purpose of the Study:

• This review examines the gut microbiome's role in improving clinical responses to ICIs for renal cancer treatment.
• To explore microbiome modulation as a therapeutic strategy in oncology.

Main Methods:

• Literature review of studies investigating the gut microbiome and its impact on ICI therapy.
• Analysis of research on microbiome modulation techniques such as probiotics and fecal microbiota transplantation (FMT).

Main Results:

• Gut microbiome composition is a critical factor in ICI efficacy.
• Microbiome modulation strategies, including probiotics and FMT, have shown promise in enhancing anti-cancer immune responses.
• These approaches can potentially overcome resistance to ICI therapy in renal cancer.

Conclusions:

• Targeting the gut microbiome represents a promising avenue for improving renal cancer treatment outcomes with ICIs.
• Further research into microbiome-based therapies is warranted to optimize cancer care.